These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37747433)
1. Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy. Meling Stokland AE; Austdal M; Nedrebø BG; Carlsen S; Hetland HB; Breivik L; Ueland HO; Watt T; Cramon PK; Løvås K; Husebye ES; Ueland GÅ J Clin Endocrinol Metab; 2024 Feb; 109(3):827-836. PubMed ID: 37747433 [TBL] [Abstract][Full Text] [Related]
2. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism. Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765 [No Abstract] [Full Text] [Related]
3. Radioiodine therapy versus antithyroid medications for Graves' disease. Ma C; Xie J; Wang H; Li J; Chen S Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370 [TBL] [Abstract][Full Text] [Related]
4. Audit of long-term treatment outcomes of thyrotoxicosis in a single-centre virtual clinic: The utility of long-term antithyroid drugs. Levy MJ; Reddy N; Price D; Bhake R; Bremner E; Barrowcliffe M; Kieffer V; Robinson C; Zaccardi F; Howlett TA Clin Endocrinol (Oxf); 2022 Nov; 97(5):643-653. PubMed ID: 35274339 [TBL] [Abstract][Full Text] [Related]
5. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies. Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649 [TBL] [Abstract][Full Text] [Related]
6. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children]. Chen DY; Chen TH Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551 [TBL] [Abstract][Full Text] [Related]
7. The tale of radioiodine and Graves' orbitopathy. Ponto KA; Zang S; Kahaly GJ Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895 [TBL] [Abstract][Full Text] [Related]
8. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey. Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296 [TBL] [Abstract][Full Text] [Related]
13. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis. Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030 [TBL] [Abstract][Full Text] [Related]
15. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial. Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of Graves' Disease Patients Following Antithyroid Drugs, Radioactive Iodine, or Thyroidectomy as the First-line Treatment. Liu X; Wong CKH; Chan WWL; Tang EHM; Woo YC; Lam CLK; Lang BHH Ann Surg; 2021 Jun; 273(6):1197-1206. PubMed ID: 33914484 [TBL] [Abstract][Full Text] [Related]
17. Graves' Disease: Can It Be Cured? Wiersinga WM Endocrinol Metab (Seoul); 2019 Mar; 34(1):29-38. PubMed ID: 30912336 [TBL] [Abstract][Full Text] [Related]
18. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Watt T; Cramon P; Bjorner JB; Bonnema SJ; Feldt-Rasmussen U; Gluud C; Gram J; Hansen JL; Hegedüs L; Knudsen N; Bach-Mortensen P; Nolsøe R; Nygaard B; Pociot F; Skoog M; Winkel P; Rasmussen AK Trials; 2013 Apr; 14():119. PubMed ID: 23782950 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy. Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161 [TBL] [Abstract][Full Text] [Related]
20. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]